Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Surface Logix has announced positive results in its randomized, double-blind, placebo-controlled crossover Phase IIa clinical trial of oral SLx-2101 in hypertension.
Subscribe to our email newsletter
The study in 60 patients with uncontrolled hypertension demonstrated that SLx-2101 caused clinically significant reductions in blood pressure and was well-tolerated. The trial was designed to examine the safety, tolerability and effect on blood pressure in patients of repeat oral doses of SLx-2101 once daily for up to 14 days.
Jim Mahoney, president and CEO of Surface Logix, said: “These data confirm the promise of efficacy seen in earlier clinical trials, and we plan to initiate a Phase IIb study of SLx-2101 in hypertension in the third quarter of 2008. We believe that with our demonstrated 24-hour coverage from once-daily dosing and excellent tolerability profile, we will be able to uniquely position SLx-2101 in several segments of the hypertension market.”